Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activity

Chaolin Huang, Yuanhong Chen, Hang Liu, Jing Yang, Xuejing Song, Junping Zhao, Na He, Chengji Zhou, Yongping Wang, Changjiang Huang, Qiaoxiang Dong

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Pharmacological targeting of breast cancer stem cells (CSCs) is highly promising for the treatment of breast cancer, as the small population of CSCs is responsible for tumor initiation, progression, recurrence and chemo-resistance. Celecoxib is one of the most commonly used non-steroidal anti-inflammatory drugs (NSAIDs), which have chemo-preventive activity against cancers, including breast cancer and colorectal cancer. However, the mechanisms by which NSAIDs exert its cancer prevention effects have yet been completely understood. In the present study, we investigated for the first time the effect of celecoxib on breast CSCs inhibition and its potential molecular mechanisms. Our results demonstrated that celecoxib suppresses CSC self-renewal, sensitizes chemo-resistance, inhibits epithelial to mesenchymal transition (EMT), and attenuates metastasis and tumorigenesis. Further exploring the underlying mechanism revealed that celecoxib targets breast CSCs by inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activity. Our findings suggest that celecoxib, by targeting CSCs, may be used as an adjuvant chemotherapy drug to improve breast cancer treatment outcomes.

Original languageEnglish (US)
Pages (from-to)115254-115269
Number of pages16
JournalOncotarget
Volume8
Issue number70
DOIs
StatePublished - Jan 1 2017

Keywords

  • Celecoxib
  • CSCs
  • EMT
  • PGE
  • Wnt pathway

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E<sub>2</sub> and down-regulating the Wnt pathway activity'. Together they form a unique fingerprint.

  • Cite this

    Huang, C., Chen, Y., Liu, H., Yang, J., Song, X., Zhao, J., He, N., Zhou, C., Wang, Y., Huang, C., & Dong, Q. (2017). Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activity. Oncotarget, 8(70), 115254-115269. https://doi.org/10.18632/oncotarget.23250